@shanmugarajan.bsky.social
"These findings were extended to human organoid models of treatment-refractory MSS-CRC liver metastases, establishing FAP-CAR-IL-15 iNKT cells as a promising strategy to overcome immunotherapy resistance in solid tumors.
November 21, 2025 at 2:59 PM
"These findings were extended to human organoid models of treatment-refractory MSS-CRC liver metastases, establishing FAP-CAR-IL-15 iNKT cells as a promising strategy to overcome immunotherapy resistance in solid tumors.
Honored that Prof. Anna Dimberg, a member of the Royal Swedish Academy of Sciences wrote a commentary in PNAS on our paper: “Wnt inhibition alleviates resistance to anti-PD1 therapy in glioblastoma.”
🧠 pnas.org/doi/10.1073/...
🗞 pnas.org/doi/10.1073/...
#Glioblastoma #Immunotherapy #PNAS
🧠 pnas.org/doi/10.1073/...
🗞 pnas.org/doi/10.1073/...
#Glioblastoma #Immunotherapy #PNAS
October 29, 2025 at 3:40 PM
Honored that Prof. Anna Dimberg, a member of the Royal Swedish Academy of Sciences wrote a commentary in PNAS on our paper: “Wnt inhibition alleviates resistance to anti-PD1 therapy in glioblastoma.”
🧠 pnas.org/doi/10.1073/...
🗞 pnas.org/doi/10.1073/...
#Glioblastoma #Immunotherapy #PNAS
🧠 pnas.org/doi/10.1073/...
🗞 pnas.org/doi/10.1073/...
#Glioblastoma #Immunotherapy #PNAS
🔗 Check out the OncoDaily feature here: lnkd.in/eb-VTa67
#Glioblastoma #GBM #BrainCancer #CancerImmunotherapy #Immunotherapy #TME #antiPD1 #PNAS #OncoDaily #ResearchHighlight
#Glioblastoma #GBM #BrainCancer #CancerImmunotherapy #Immunotherapy #TME #antiPD1 #PNAS #OncoDaily #ResearchHighlight
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
September 17, 2025 at 7:04 PM
🔗 Check out the OncoDaily feature here: lnkd.in/eb-VTa67
#Glioblastoma #GBM #BrainCancer #CancerImmunotherapy #Immunotherapy #TME #antiPD1 #PNAS #OncoDaily #ResearchHighlight
#Glioblastoma #GBM #BrainCancer #CancerImmunotherapy #Immunotherapy #TME #antiPD1 #PNAS #OncoDaily #ResearchHighlight
Reposted
This work was recently published in PNAS by our team and collaborators. Read the full paper here www.pnas.org/doi/10.1073/...
PNAS
Proceedings of the National Academy of Sciences (PNAS), a peer reviewed journal of the National Academy of Sciences (NAS) - an authoritative source of high-impact, original research that broadly spans...
www.pnas.org
September 17, 2025 at 4:40 PM
This work was recently published in PNAS by our team and collaborators. Read the full paper here www.pnas.org/doi/10.1073/...
Reposted
Excited to share our recent discovery on combination therapy strategies to overcome treatment resistance in glioblastoma, now highlighted by
@MassGeneralNew @harvardmed.bsky.social www.massgeneralbrigham.org/en/about/new...
@MassGeneralNew @harvardmed.bsky.social www.massgeneralbrigham.org/en/about/new...
Research Spotlight: Combination Therapy Shows Promise for Overcoming Treatment Resistance in Glioblastoma | Mass General Brigham
Glioblastoma (GBM) is a deadly brain cancer. Current treatments, including a type of immunotherapy called anti-PD1, don’t work well for most patients. New research has identified a promising new treat...
www.massgeneralbrigham.org
September 17, 2025 at 4:40 PM
Excited to share our recent discovery on combination therapy strategies to overcome treatment resistance in glioblastoma, now highlighted by
@MassGeneralNew @harvardmed.bsky.social www.massgeneralbrigham.org/en/about/new...
@MassGeneralNew @harvardmed.bsky.social www.massgeneralbrigham.org/en/about/new...